E2112-Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor-positive advanced breast cancer represent a death knell?
- PMID: 35352486
- PMCID: PMC9058311
- DOI: 10.1111/1759-7714.14399
E2112-Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor-positive advanced breast cancer represent a death knell?
Conflict of interest statement
The author declares no competing interests.
Comment on
-
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.J Clin Oncol. 2021 Oct 1;39(28):3171-3181. doi: 10.1200/JCO.21.00944. Epub 2021 Aug 6. J Clin Oncol. 2021. PMID: 34357781 Free PMC article. Clinical Trial.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
